Zepbound and Wegovy are both once-weekly injections approved for weight management, and the short answer on zepbound vs wegovy is this: tirzepatide, sold as Zepbound, produced more average weight loss in the one trial that tested the two drugs directly against each other. Semaglutide, sold as Wegovy, has the longer track record and an approved use for lowering cardiovascular risk. Their side effect profiles look broadly similar. What you pay is driven far less by the molecule than by your insurance plan, your documented diagnoses and the purchase route you use.
Why it matters: Most people stall or switch because of coverage and cost, not because they picked the wrong drug first.
Zepbound vs Wegovy: the short version
- Same class, different design: Wegovy acts on one gut hormone receptor, Zepbound acts on two.
- Bigger average loss with tirzepatide: both the separate registration trials and the single head-to-head study point the same way.
- Nearly identical warnings: both carry the same boxed warning about thyroid C-cell tumours and the same contraindications.
- Different extra indications: semaglutide is approved to reduce cardiovascular events in certain adults; tirzepatide is approved for moderate to severe obstructive sleep apnea with obesity.
- Price depends on the route: plan copay, manufacturer self-pay vials and telehealth cash programs can produce wildly different monthly numbers for the same prescription.
Two molecules, two mechanisms
Semaglutide is a GLP-1 receptor agonist, which means it mimics glucagon-like peptide-1, a hormone your gut releases after eating. It slows how fast the stomach empties and reduces appetite signalling in the brain. Tirzepatide does the same job at the GLP-1 receptor and also activates the GIP receptor (glucose-dependent insulinotropic polypeptide, a second gut hormone involved in appetite and insulin release). That dual action is the main biological difference between the two drugs.
Both names are brands, not molecules. Semaglutide is also sold as Ozempic and Rybelsus for type 2 diabetes, and tirzepatide is also sold as Mounjaro. The active ingredient is the same across those brands, but the approved use, the maximum dose and the way insurers handle the claim are not. Our molecule-level explainers cover each one in more depth: Tirzepatide Dosing And Side Effects and Compounded Versus Brand Semaglutide.
Both start at a low dose and step up roughly every four weeks, which is how prescribers limit nausea. Wegovy titrates through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg to a 2.4 mg maintenance dose. Zepbound starts at 2.5 mg and can rise to 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg, so there are more maintenance options at the top end. A prescriber decides where you stop based on response and tolerability.
How much weight people lost in the trials
The registration trials were run separately, on different groups, so they are not a clean comparison.
In the pivotal obesity trials, adults on the highest tirzepatide dose lost about 21% of their body weight over 72 weeks, while adults on semaglutide 2.4 mg lost about 15% over 68 weeks. (FDA)The one direct test came later. In a 72 week head-to-head trial published in the New England Journal of Medicine in 2025, adults taking tirzepatide lost around 20% of their starting weight on average, compared with around 14% on semaglutide. The gap was consistent, but these are averages. Response varies widely: some people on semaglutide lose more than the tirzepatide average, and a minority on either drug lose very little.
Two caveats matter more than the headline numbers. First, trial participants received structured diet and activity counselling alongside the injection, and real-world results are usually smaller. Second, weight comes back when the drug stops, for both molecules. Studies that withdrew treatment saw most of the loss regained, which is why clinicians increasingly describe these as long-term medications rather than a course.
Side effects and safety: mostly shared, with a few differences
The common side effects are the same list for both drugs: nausea, vomiting, diarrhoea, constipation, stomach pain, burping, fatigue and injection-site reactions. They cluster around dose increases and usually ease as the body adjusts. Slower titration is the standard response when symptoms are rough.
The serious risks are also shared. Both labels warn about pancreatitis (inflammation of the pancreas), gallbladder problems including gallstones, acute kidney injury caused by dehydration from prolonged vomiting or diarrhoea, severe allergic reactions and low blood sugar when combined with insulin or a sulfonylurea. Both labels also note delayed stomach emptying, which matters before surgery or any procedure involving anaesthesia. Tell the anaesthesia team you are on one of these drugs.
Both carry a boxed warning, the strongest warning the FDA applies, about thyroid C-cell tumours seen in rodents. Neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or by anyone who has had a serious reaction to the active ingredient. Full prescribing information for both products is published on the NIH DailyMed label database.
Semaglutide’s label carries one extra flag: worsening of diabetic retinopathy was seen in people with type 2 diabetes, so eye monitoring is relevant for that group. Wegovy’s label also advises stopping at least two months before a planned pregnancy, because the drug stays in the body a long time. Neither drug is for use during pregnancy. Seek urgent care for severe, persistent abdominal pain that spreads to the back, repeated vomiting that stops you keeping fluids down, or signs of a serious allergic reaction.
Where the labels differ
| Factor | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptors targeted | GLP-1 and GIP | GLP-1 |
| Maintenance doses | 5 mg to 15 mg weekly | 2.4 mg weekly |
| Extra approved use | Obstructive sleep apnea with obesity | Cardiovascular risk reduction in certain adults |
| Approved ages | Adults | Adults and adolescents 12 and older |
| Also sold as | Mounjaro, for type 2 diabetes | Ozempic and Rybelsus, for type 2 diabetes |
Who each drug is approved for
The weight-management criteria are the same for both: a body mass index of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnea. Insurers lean heavily on that threshold, and so do telehealth intake forms, so it is worth knowing where you sit before a first visit.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
The extra indications are where the choice can become straightforward. If you have established cardiovascular disease plus obesity or overweight, semaglutide’s approved cardiovascular indication gives a prescriber a clearer argument and sometimes gives the plan a reason to cover it. If you have moderate to severe obstructive sleep apnea with obesity, tirzepatide’s sleep apnea indication does similar work. In both cases the extra diagnosis has to be documented in your chart, not just mentioned in a visit.
Adolescent care is a real difference too: Wegovy is approved from age 12 for adolescents at or above the 95th BMI percentile, while Zepbound is approved for adults.
What you actually pay for zepbound vs wegovy
List prices for both run well over a thousand dollars a month, and almost nobody pays that. The number that lands on your card depends on which of four routes you end up in: a covered plan benefit, a manufacturer savings card, a manufacturer self-pay pharmacy, or a cash telehealth program. Those routes can differ by several hundred dollars a month for the same molecule.
If you have commercial insurance
Many employer plans exclude weight-loss drugs outright, and an exclusion is not something an appeal usually fixes. Where there is coverage, expect prior authorization, and often step therapy that makes you try a preferred product first. Plans commonly ask for documented BMI, weight-related conditions, and sometimes evidence of a supervised diet and activity effort. Denials at first pass are normal rather than exceptional, and a resubmission with the missing documentation is the usual path.
Two numbers decide whether coverage is actually cheaper: your copay or coinsurance tier, and where you are in your deductible. Coinsurance on a high-cost drug during the deductible phase can cost more than a cash program. Providers that can bill insurance for these prescriptions are listed below.
No provider matches that filter. .
See every provider we track, with filters and sorting
If you are paying cash
Both manufacturers now sell directly to self-pay patients, Eli Lilly through LillyDirect and Novo Nordisk through NovoCare Pharmacy, usually in single-dose vials rather than pens. Those programs changed the cash market substantially. Telehealth programs sit alongside them, bundling the visit, dose adjustments and messaging into a membership fee, with the medication billed separately or included depending on the provider. In our tracked data, cash prices for tirzepatide programs start at $99 a month and semaglutide programs at $99. Pricing here is desk-checked against live provider sites and re-checked monthly, and you can see how the rest of the scoring works in How We Score Providers.
No provider matches that filter. .
See every provider we track, with filters and sorting
Before you treat any quoted monthly figure as your real cost, confirm:
- What the fee buys: visits, dose changes and messaging, or just the prescription.
- Whether medication is separate: a low membership fee often sits on top of the drug cost.
- Which strength it covers: higher maintenance doses frequently cost more.
- Whether it is an intro rate: ask what month four costs, not month one.
- Lab and monitoring costs: some programs include them, some bill separately.
- Cancellation terms: whether you are in a multi-month commitment.
Annual arithmetic is where these decisions usually resolve, because a difference of a hundred dollars a month is more than a thousand dollars a year.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
Medicare, Medicaid and compounded versions
Medicare Part D cannot cover a drug prescribed purely for weight loss, but plans may cover one of these products when it is prescribed for an approved non-weight indication, such as cardiovascular risk reduction. Coverage is plan by plan, so check your formulary and the exact indication your prescriber documents. State Medicaid programs vary widely on obesity drugs.
Compounded copies filled the gap during the shortages of 2023 and 2024, when pharmacies were permitted to compound versions of drugs on the FDA shortage list. Those shortage designations have since ended, which narrowed the legal space for mass compounding of straightforward copies. If a program offers compounded tirzepatide or semaglutide, ask which licensed pharmacy fills it and on what basis, and read our class comparison in the GLP-1 Telehealth Comparison.
Switching between them
Switching is common, usually for one of three reasons: side effects that do not settle, weight loss that plateaus well short of the goal, or a formulary change that strands you on a product your plan stopped covering. The clinical mechanics are not complicated, but the dose does not transfer. There is no simple conversion between 2.4 mg of semaglutide and any tirzepatide dose, so most prescribers restart titration at or near the bottom and step up again.
Expect the early side effects to return for a few weeks. Expect a paperwork delay too, since a new prior authorization is usually required, and some plans will want evidence that the first drug failed or was not tolerated. Keep your own record of doses tried, dates and symptoms: that log is what makes the second authorization move faster.
Quick tip: Ask your prescriber to note the specific reason for the switch in the chart, because plan reviewers read that field.
Where to go from here
Zepbound vs Wegovy is only partly a clinical question. If your plan covers one of them at a workable copay, that is usually the practical answer, whatever the trial averages say. If you are paying cash, compare the manufacturer self-pay route against telehealth programs on total monthly cost, not on the headline fee. And if you have a documented condition that matches one of the extra indications, raise it early, because it can change both the prescribing decision and the coverage one.
From there, you can compare current program costs with our Cost Check Tool, browse the Telehealth Provider Directory to see which platforms treat weight management in your state, or work through the eligibility and dose numbers using our Free Health Calculators. The Medication Guide Index covers the rest of the class, including the oral options.
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.


